Top Page
Venus Medtech (Hangzhou), Inc. Class H
(2500)
Venus Medtech (Hangzhou), Inc. Class H (2500) vs. iShares MSCI Hong Kong ETF (EWH)
Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model
Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 427.25M | 470.83M | 491.37M | 406.46M | 415.86M | 276.05M |
| Gross Profit | 323.97M | 367.75M | 389.20M | 314.00M | 324.34M | 227.28M |
| EBITDA | -572.39M | -612.96M | -547.84M | -999.37M | -324.03M | -152.83M |
| Net Income | -642.59M | -714.31M | -703.75M | -1.06B | -373.64M | -182.87M |
Balance Sheet | ||||||
| Total Assets | 3.12B | 3.25B | 4.41B | 5.28B | 5.11B | 4.32B |
| Cash, Cash Equivalents and Short-Term Investments | 293.31M | 305.70M | 781.64M | 1.88B | 2.96B | 2.75B |
| Total Debt | 493.59M | 369.09M | 826.19M | 899.64M | 70.78M | 32.76M |
| Total Liabilities | 1.05B | 1.04B | 1.49B | 1.65B | 477.61M | 461.19M |
| Stockholders Equity | 2.07B | 2.21B | 2.92B | 3.61B | 4.55B | 3.82B |
Cash Flow | ||||||
| Free Cash Flow | -56.51M | -17.82M | -872.93M | -908.23M | -602.08M | -361.05M |
| Operating Cash Flow | -58.51M | 23.74M | -610.02M | -729.46M | -456.92M | -237.00M |
| Investing Cash Flow | 17.23M | -19.90M | -346.86M | -1.07B | -653.04M | -297.94M |
| Financing Cash Flow | -149.37M | -487.34M | -173.99M | 635.14M | 1.39B | 927.75M |
Venus Medtech (Hangzhou), Inc. Class H Technical Analysis
Venus Medtech (Hangzhou), Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.98B | 42.38 | 3.84% | ― | 32.93% | ― | |
58 Neutral | HK$8.49B | 46.07 | 4.99% | 0.48% | 35.01% | 483.73% | |
53 Neutral | HK$1.26B | -1.79 | -26.80% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.43B | -18.03 | -11.20% | ― | 29.25% | 9.02% | |
43 Neutral | HK$5.03B | 359.09 | 0.22% | ― | -4.38% | ― | |
40 Neutral | HK$1.09B | -8.51 | -8.93% | ― | -30.60% | 28.61% |
Venus Medtech (Hangzhou), Inc. Class H Corporate Events
Venus Medtech (Hangzhou) Inc. has informed shareholders that Cardiovalve Ltd. and MTH IP, L.P. have filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Edwards Lifesciences over U.S. Patent No. 10,702,385, covering an implant for heart valves. The case, which targets Edwards’ PASCAL Precision Transcatheter Valve Repair System and follows a prior U.S. Federal Circuit decision upholding the patent’s key claims, remains at an early stage with potential claim amounts and outcomes still uncertain, and Venus Medtech has cautioned investors to exercise care when trading its shares as it monitors developments and plans further updates as required under Hong Kong listing rules.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech (Hangzhou) Inc., a Hong Kong-listed mainland Chinese cardiovascular device developer, operates through entities such as wholly owned subsidiary Cardiovalve Ltd. and joint venture MTH IP, L.P. to advance its portfolio of innovative heart-related medical technologies in global markets. The company has issued a clarification announcement following media reports on a patent infringement lawsuit filed by Cardiovalve and MTH IP in the U.S. District Court for the District of Delaware against Edwards Lifesciences, stating that after reasonable inquiry it is not aware of any information requiring disclosure to prevent a false market or any inside information that must be announced under Hong Kong listing and securities regulations, and advising shareholders and potential investors to exercise caution when dealing in its shares.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech (Hangzhou) Inc. has agreed to dispose of its entire remaining stake in an unnamed investee company, selling approximately 1.05% of the investee’s fully diluted share capital for US$15 million to a wholly owned subsidiary of Broncus. The transaction, classified as a discloseable transaction under Hong Kong listing rules, will result in Venus Medtech’s subsidiary exiting its investment in the company entirely, signaling a reallocation of capital that could support the group’s core operations while modestly reshaping its investment portfolio without triggering higher-level shareholder approval requirements.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech (Hangzhou) Inc. has announced that it has formally submitted all application materials for EU CE MDR marking to a European Notified Body for its Cardiovalve transcatheter tricuspid valve replacement system, a key step toward potential commercialization in Europe. The Cardiovalve System is designed to treat both mitral and tricuspid regurgitation using a transfemoral approach that aims to enhance safety, with a large annulus accommodating up to 55 mm to cover about 95% of patients and a short frame intended to reduce left ventricular outflow tract obstruction risk, positioning the product as a competitive, user-friendly option in the structural heart device market, though the company cautions there is no guarantee it will ultimately reach the market and advises investors to exercise caution.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech (Hangzhou) Inc. announced that the resolution proposed at their extraordinary general meeting was successfully passed. The resolution involved the approval of terms and transactions under a Disposal Agreement, which was unanimously supported by shareholders who attended the meeting. This development signifies a strategic move for the company, potentially impacting its operational focus and market positioning.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech has announced interim clinical results from its Cardiovalve Target Study, highlighting the safety and performance of its transcatheter valve replacement system. The study, involving 125 patients across multiple countries, showed promising results with a high success rate and significant improvements in patients’ cardiac function and quality of life. The 12-month follow-up results demonstrated sustained efficacy and safety, reinforcing the device’s potential impact on patient care and the company’s positioning in the cardiovascular device market.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech (Hangzhou) Inc. has announced a supplemental agreement regarding the issuance of convertible bonds under a general mandate. The proceeds from this issuance will be used to accelerate the development of the company’s core product pipeline and to supplement general corporate working capital. The company has outlined specific terms for the bridge loan provided by the subscriber, including interest rates and repayment conditions. This strategic financial move is expected to enhance Venus Medtech’s operational capabilities and optimize its capital structure, potentially strengthening its position in the medical technology market.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech (Hangzhou) Inc. has announced an extraordinary general meeting to be held on November 28, 2025, to approve a Disposal Agreement with Hangzhou Binjiang Urban Construction Development Co., Ltd. This agreement involves the disposal of construction in progress and associated land use rights, potentially impacting the company’s operational focus and asset management strategy.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
Venus Medtech has announced a major transaction involving the disposal of property related to its Qiming Healthcare Life Science Industrial Park project, selling it for RMB374,563,969. This move aligns with the company’s strategic shift to concentrate on its core heart valve business, following a previously recognized impairment loss of RMB126.0 million related to the project.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.